CureVac Expands Covid Vax Trial to Include Variant

 CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company

developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced plans to 
expand and further specify the protocols of its ongoing late-stage clinical trials with CVnCoV, its COVID-19 vaccine 
candidate. 
CVnCoV efficacy is currently being evaluated in the pivotal HERALD Phase 2b/3 trial in Europe and Latin America. Rapid 
distribution of new virus variants in the countries where the study is conducted supports the need for further analysis 
specification for the anticipated case-driven interim analysis. This will allow to determine efficacy of the vaccine 
candidate for select variants. The company has ongoing discussions with the European Medicines Agency (EMA) to 
potentially include an amendment related to select virus strains in the study. 
For its Phase 2a dose-confirmation trial in older adults in Peru and Panama, CureVac has submitted a protocol amendment 
to include a secondary objective for vaccine efficacy. The study initially aimed to evaluate safety, reactogenicity and 
immunogenicity of CVnCoV in adults. Expanded trial analysis is expected to allow for collection of relevant efficacy 
data which includes the important group of approximately 270 participants above the age of 60, treated with 12µg of 
CVnCoV. 
"Our goal is to offer the public and especially the vulnerable older age groups the best possible protection against 
the virus and its variants with our vaccine candidate", said Ulrike Gnad-Vogt, Interim Chief Development Officer of 
CureVac.

https://www.marketscreener.com/quote/stock/CUREVAC-N-V-110869003/news/PRESS-RELEASE-nbsp-CureVac-Expands-CVnCoV-Covid-19-Vaccine-Candidate-Clinical-Trial-Analyses-to-In-32753319/